Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: To investigate the safety, tolerability, pharmacokinetics, and efficacy of apilimod mesylate, an oral interleukin‐12 (IL‐12)/IL‐23 inhibitor, in patients with rheumatoid arthritis (RA). Methods: We performed a phase IIa, randomized, double‐blind, placebo‐controlled proof‐of‐concept study of apilimod, in combination with methotrexate, in 29 patients with active RA (3:1 ratio of apilimod‐treated to placebo‐treated patients) in 3 stages. Patients received apilimod 100 mg/day or placebo for 4 weeks (stage 1) or 8 weeks (stage 2). In stage 3, patients received apilimod 100 mg twice a day or placebo for 8 weeks, with an optional extension of 4 weeks. Clinical response (Disease Activity Score in 28 joints [DAS28] and American College of Rheumatology [ACR] criteria) was assessed throughout; synovial tissue samples collected at baseline and on day 29 (stages 1 and 2) or day 57 (stage 3) were stained for cellular markers and cytokines for immunohistochemistry analysis. Results: While only mild adverse events were observed in stages 1 and 2, in stage 3, all patients experienced headache and/or nausea. Among apilimod‐treated patients (100 mg/day), there was a small, but significant, reduction in the DAS28 on day 29 and day 57 compared with baseline. ACR20 response was reached in only 6% of patients on day 29 and 25% of patients on day 57, similar to the percentage of responders in the placebo group. Increasing the dosage (100 mg twice a day) did not improve clinical efficacy. Consistent with clinical results, apilimod did not have an effect on expression of synovial biomarkers. Of importance, we also did not observe an effect of apilimod on synovial IL‐12 and IL‐23 expression. Conclusion: Our results do not support the notion that IL‐12/IL‐23 inhibition by apilimod is able to induce robust clinical improvement in RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., & Cua, D. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030896 · Cited by 1,669
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Sands, B. E., Jacobson, E. W., Sylwestrowicz, T., Younes, Z., Dryden, G., Fedorak, R., & Greenbloom, S. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21159 · Cited by 114
Self-citation
Cited by
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Lysosomes as a therapeutic target
Bonam, S. R., Wang, F., & Muller, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0036-1 · Cited by 759
The IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Gayle, S., Landrette, S., Beeharry, N., Conrad, C., Hernandez, M., Beckett, P., Ferguson, S. M., Mandelkern, T., Zheng, M., Xu, T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736892 · Cited by 202
“cell lymphoma (5), chronic lymphocytic leukemia- small lymphocytic lymphoma (5), mantle cell lymphoma (4), mycosis fungoides-Sezary syndrome (3), peripheral T-cell lymphoma unspecified (1), T-cell large granular lymphocytic leukemia (1), and”
Background
Metadata
- Authors
- Krausz, S., Boumans, M. J. H., Gerlag, D. M., Lufkin, J., van Kuijk, A. W. R., Bakker, A., de Boer, M., Lodde, B. M., Reedquist, K. A., Jacobson, E. W., O'Meara, M., & Tak, P. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-05-25
- Volume
- 64
- Issue
- 6
- Pages
- 1750-1755
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2061948993
- Cited by
- 85
- References
- 3
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.